Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2163-2169

  Choi, Yung Hyun ^a   Yoo, Young Hyun ^b  

^a Dong Eui University   (South Korea)

^b Dong A University   (South Korea)

Author keywords

Apoptosis; G2 M arrest; P21WAF1 CIP1; Taxol

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG; WEE1 KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL LYSATE; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN CONDENSATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA STRUCTURE; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LOCALIZATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; MCF-7 CELLS; NUCLEAR PROTEINS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; PROMOTER REGIONS, GENETIC; PROTEIN-TYROSINE KINASES; UP-REGULATION;

EID: 84868109639     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2060     Document Type: Conference Paper

References (37)

1. Burhans WC and Heintz NH: The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 47:1282-1293, 2009.
2. Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783, 2006. (Pubitemid 46628473)
3. Ruetz S, Fabbro D, Zimmermann J, Meyer T and Gray N: Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr Med Chem Anticancer Agents 3:1-14, 2003. (Pubitemid 36131630)
4. Stark GR and Taylor WR: Control of the G2/M transition. Mol Biotechnol 32:227-248, 2006.
5. Han SJ and Conti M: New pathways from PKA to the Cdc2/cyclin B complex in oocytes: Wee1B as a potential PKA substrate. Cell Cycle 5:227-231, 2006. (Pubitemid 43213488)
6. De Cárcer G, Pérez De Castro I and Malumbres M: Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14:969-985, 2007 (Pubitemid 46672634)
7. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400-414, 2009.
8. Brown L, Boswell S, Raj L and Lee SW: Transcriptional targets of p53 that regulate cellular proliferation. Crit Rev Eukaryot Gene Expr 17:73-85, 2007. (Pubitemid 46511616)
9. Boulaire J, Fotedar A and Fotedar R: The functions of the cdkcyclin kinase inhibitor p21WAF1. Pathol Biol 48:190-202, 2000. (Pubitemid 30318121)
10. Cazzalini O, Scovassi AI, Savio M, Stivala LA and Prosperi E: Multiple roles of the cell cycle inhibitor p21 (CDKN1A) in the DNA damage response. Mutat Res 704:12-20, 2010.
11. Lou Z and Chen J: Mammalian DNA damage response pathway. Adv Exp Med Biol 570:425-455, 2005. (Pubitemid 47413182)
12. Krysko DV, Van Den Berghe T, D'Herde K and Vandenabeele P: Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 44:205-221, 2008. (Pubitemid 351296447)
13. Sinclair A, Yarranton S and Schelcher C: DNA-damage response pathways triggered by viral replication. Expert Rev Mol Med 8:1-11, 2006.
14. Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408-9421, 2005.
15. Raucher D, Moktan S, Massodi I and Bidwell GL III: Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 6:1049-1064, 2009.
16. Hainaut P: The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 7:76-82, 1995.
17. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E and Los M: Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10:13-29, 2007. (Pubitemid 46636381)
18. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327, 1971.
19. Steed H and Sawyer MB: Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8:803-815, 2007. (Pubitemid 47288979)
20. Jassem J, Carroll C, Ward SE, Simpson E and Hind D: The clinical effcacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer 45:2749-2758, 2009.
21. Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P and Rathelot P: Albumin-bound Paclitaxel: the benefic of this new formulation in the treatment of various cancers. J Chemother 23:59-66, 2011.
22. Trudeau ME: Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 6:443-457, 1996.
23. Pienta KJ: Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 28:S3-S7, 2001.
24. Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci 13:134-136, 1992.
25. Donaldson KL, Goolsby GL, Kiener PA and Wahl AF: Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5:1041-1050, 1994. (Pubitemid 24312279)
26. Liu Y, Bhalla K, Hill C and Priest DG: Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 48:1265-1272, 1994. (Pubitemid 24298378)
27. Kang BR, Kim H, Nam SH, Yun EY, Kim SR, Ahn MY, Chang JS and Hwang JS: CopA3 peptide from Copris tripartitus induces apoptosis in human leukemia cells via a caspase-independent pathway. BMB Rep 45:85-90, 2012.
28. Jang JY, Kim MK, Jeon YK, Joung YK, Park KD and Kim CW: Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the downregulation of ABCG2 in breast cancer stem-like cells. Exp Mol Med 44:251-259, 2012.
29. Vermeulen K, Van Bockstaele DR and Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann Hematol 84:627-639, 2005. (Pubitemid 41554237)
30. Widlak P: The DFF40/CAD endonuclease and its role in apoptosis. Acta Biochim Pol 47:1037-1044, 2000.
31. Higuchi Y: Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. Biochem Pharmacol 66:1527-1535, 2003. (Pubitemid 38373343)
32. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly (ADP-ribose polymerase by a proteinase with properties like ICE. Nature 371:346-347, 1994. (Pubitemid 24300618)
33. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:799-805, 1994.
34. Rodriguez I, Ody C, Araki K, Garcia I and Vassalli P: An early and massive wave of germinal cell apoptosis is required for the development of functional spermatogenesis. EMBO J 16:2262-2270, 1997. (Pubitemid 27260376)
35. BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960-1169, 1994.
36. Strasser A, Harris AW, Jacks T and Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339, 1994.
37. Negrini M, Sabbioni S, Haldar S, Possati L, Castagnoli A, Corallini A, Barbanti-Brodani G and Croce CM: Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res 54:1818-1824, 1994.